Crizotinib Resistance Gene Identified | Lung Cancer Dispatch |

Researchers have found that mutation of a gene called MED12 makes non-small cell lung cancer (NSCLC) tumors resistant to the drug crizotinib (Xalkori®). Patients who take crizotinib often develop resistance to the drug as a result of accumulating mutations. This study suggests that drugs called TGF-betaR inhibitors, which are already being tested in clinical trials, may counteract crizotinib resistance in patients with MED12 mutations.